Press release
Primary Progressive Multiple Sclerosis Pipeline Assessment (2024 Updates): EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, MOA, ROA and Companies by DelveInsight | AB Science, Sanofi, Medici Nova, MedDay Pharma, Roche, Mapi Pharma, Atara Biotherapeu
Primary Progressive Multiple Sclerosis Pipeline
"Primary Progressive Multiple Sclerosis Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Primary Progressive Multiple Sclerosis Therapeutics Market.
The report provides a detailed description of the Primary Progressive Multiple Sclerosis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Primary Progressive Multiple Sclerosis Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Primary Progressive Multiple Sclerosis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Primary Progressive Multiple Sclerosis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Progressive Multiple Sclerosis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Primary Progressive Multiple Sclerosis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Primary Progressive Multiple Sclerosis treatment market.
Learn More about the Clinical and Commercial Development Activities in the Primary Progressive Multiple Sclerosis Therapeutics Domain @
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Primary Progressive Multiple Sclerosis Therapeutics Analysis
Around 10+ noteworthy pharma and biotech companies are actively involved in the development of therapies for Primary Progressive Multiple Sclerosis (PPMS). Among these, certain companies stand out due to their advancement in the development pipeline, particularly in the most advanced stage-Phase III clinical trials.
Primary Progressive Multiple Sclerosis Companies in the Therapeutics Market Include:
• Atara Biotherapeutics
• AB Science
• Sanofi
• Medici Nova
• MedDay Pharma
• Roche
• Mapi Pharma
• Brainstorm-Cell Therapeutics
And Many Others
Emerging and Marketed Primary Progressive Multiple Sclerosis Therapies Covered in the Report Include:
• Tolebrutinib: Sanofi
• ATA 188: Atara Biotherapeutics
• Masitinib: AB Science
And Many More
Get an in-depth Assessment of the Emerging Therapies and Primary Progressive Multiple Sclerosis Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The Report Covers the Emerging Primary Progressive Multiple Sclerosis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Route of Administration
Primary Progressive Multiple Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Request for Sample PDF to Understand More About the Primary Progressive Multiple Sclerosis Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Report Introduction
2. Executive Summary
3. Primary Progressive Multiple Sclerosis Current Treatment Patterns
4. Primary Progressive Multiple Sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Primary Progressive Multiple Sclerosis Late-Stage Products (Phase-III)
7. Primary Progressive Multiple Sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Primary Progressive Multiple Sclerosis Discontinued Products
13. Primary Progressive Multiple Sclerosis Product Profiles
14. Primary Progressive Multiple Sclerosis Companies
15. Primary Progressive Multiple Sclerosis Drugs
16. Dormant and Discontinued Products
17. Primary Progressive Multiple Sclerosis Unmet Needs
18. Primary Progressive Multiple Sclerosis Future Perspectives
19. Primary Progressive Multiple Sclerosis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/primary-progressive-multiple-sclerosis-ppms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Alopecia Aerata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Brain Cancer Market: https://www.delveinsight.com/report-store/brain-cancer-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Biliary Tumor Market: https://www.delveinsight.com/report-store/biliary-tumor-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Reactive Arthritis Market: https://www.delveinsight.com/report-store/reactive-arthritis-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Progressive Multiple Sclerosis Pipeline Assessment (2024 Updates): EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, MOA, ROA and Companies by DelveInsight | AB Science, Sanofi, Medici Nova, MedDay Pharma, Roche, Mapi Pharma, Atara Biotherapeu here
News-ID: 3491363 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
